Cargando…
Clinical and biochemical study of d-serine metabolism among schizophrenia patients
BACKGROUND: Schizophrenia is a typical N-methyl-d-aspartate receptor (NMDA-R) hypofunction disorder. Decreased d-serine (d-Ser) levels in the periphery occur in schizophrenia and may reflect decreased availability of d-Ser to activate NMDA-R in the brain. OBJECTIVE: The objective of this study was t...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391825/ https://www.ncbi.nlm.nih.gov/pubmed/28435276 http://dx.doi.org/10.2147/NDT.S126979 |
_version_ | 1783229340867100672 |
---|---|
author | El-Tallawy, Hamdy N Saleem, Tahia H El-Ebidi, Abdallah MAA Hassan, Mohammed H Gabra, Romany H Farghaly, Wafaa MA Abo El-Maali, Nagwa Sherkawy, Hoda S |
author_facet | El-Tallawy, Hamdy N Saleem, Tahia H El-Ebidi, Abdallah MAA Hassan, Mohammed H Gabra, Romany H Farghaly, Wafaa MA Abo El-Maali, Nagwa Sherkawy, Hoda S |
author_sort | El-Tallawy, Hamdy N |
collection | PubMed |
description | BACKGROUND: Schizophrenia is a typical N-methyl-d-aspartate receptor (NMDA-R) hypofunction disorder. Decreased d-serine (d-Ser) levels in the periphery occur in schizophrenia and may reflect decreased availability of d-Ser to activate NMDA-R in the brain. OBJECTIVE: The objective of this study was to investigate the role of d-Ser metabolism in the pathogenesis of schizophrenia via biochemical assays and correlates, the serum level of d-Ser, d-serine racemase (SR) (responsible for its formation from l-serine [l-Ser]) and d-amino acid oxidase (DAAO) (responsible for its catabolism), among different clinical types of schizophrenia patients. PATIENTS AND METHODS: This cross-sectional case–control study was carried out on 100 patients and 50 controls. They were recruited from the outpatients’ psychiatric unit of the Neuropsychiatric Department of Assiut University Hospital, Upper Egypt. The type of schizophrenia was determined according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), while the severity of schizophrenia was determined according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Serum d-Ser levels were estimated using high-performance liquid chromatography (HPLC), while serum SR and DAAO were measured using commercially available enzyme-linked immunosorbent assay kits. RESULTS: There were significantly lower mean serum levels of d-Ser and SR and significantly higher mean serum levels of DAAO (P-value <0.01 for each) among schizophrenia patients when compared with the control group. Paranoid schizophrenia had the highest frequency, with a significantly lower serum levels of d-Ser and SR in the residual type and significantly higher serum levels of DAAO in undifferentiated and catatonic types. Combined receiver-operating characteristic curve for serum d-Ser, SR and DAAO indicated that the best serum level cutoff points at which schizophrenia manifestations started to appear were ≤ 61.4 mg/L for d-Ser, ≤ 15.5 pg/mL for SR and >35.6 pg/mL for DAAO. CONCLUSION: The present study confirms that disturbed d-Ser metabolism could be implicated in the pathogenesis of schizophrenia. |
format | Online Article Text |
id | pubmed-5391825 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-53918252017-04-21 Clinical and biochemical study of d-serine metabolism among schizophrenia patients El-Tallawy, Hamdy N Saleem, Tahia H El-Ebidi, Abdallah MAA Hassan, Mohammed H Gabra, Romany H Farghaly, Wafaa MA Abo El-Maali, Nagwa Sherkawy, Hoda S Neuropsychiatr Dis Treat Original Research BACKGROUND: Schizophrenia is a typical N-methyl-d-aspartate receptor (NMDA-R) hypofunction disorder. Decreased d-serine (d-Ser) levels in the periphery occur in schizophrenia and may reflect decreased availability of d-Ser to activate NMDA-R in the brain. OBJECTIVE: The objective of this study was to investigate the role of d-Ser metabolism in the pathogenesis of schizophrenia via biochemical assays and correlates, the serum level of d-Ser, d-serine racemase (SR) (responsible for its formation from l-serine [l-Ser]) and d-amino acid oxidase (DAAO) (responsible for its catabolism), among different clinical types of schizophrenia patients. PATIENTS AND METHODS: This cross-sectional case–control study was carried out on 100 patients and 50 controls. They were recruited from the outpatients’ psychiatric unit of the Neuropsychiatric Department of Assiut University Hospital, Upper Egypt. The type of schizophrenia was determined according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), while the severity of schizophrenia was determined according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Serum d-Ser levels were estimated using high-performance liquid chromatography (HPLC), while serum SR and DAAO were measured using commercially available enzyme-linked immunosorbent assay kits. RESULTS: There were significantly lower mean serum levels of d-Ser and SR and significantly higher mean serum levels of DAAO (P-value <0.01 for each) among schizophrenia patients when compared with the control group. Paranoid schizophrenia had the highest frequency, with a significantly lower serum levels of d-Ser and SR in the residual type and significantly higher serum levels of DAAO in undifferentiated and catatonic types. Combined receiver-operating characteristic curve for serum d-Ser, SR and DAAO indicated that the best serum level cutoff points at which schizophrenia manifestations started to appear were ≤ 61.4 mg/L for d-Ser, ≤ 15.5 pg/mL for SR and >35.6 pg/mL for DAAO. CONCLUSION: The present study confirms that disturbed d-Ser metabolism could be implicated in the pathogenesis of schizophrenia. Dove Medical Press 2017-04-10 /pmc/articles/PMC5391825/ /pubmed/28435276 http://dx.doi.org/10.2147/NDT.S126979 Text en © 2017 El-Tallawy et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research El-Tallawy, Hamdy N Saleem, Tahia H El-Ebidi, Abdallah MAA Hassan, Mohammed H Gabra, Romany H Farghaly, Wafaa MA Abo El-Maali, Nagwa Sherkawy, Hoda S Clinical and biochemical study of d-serine metabolism among schizophrenia patients |
title | Clinical and biochemical study of d-serine metabolism among schizophrenia patients |
title_full | Clinical and biochemical study of d-serine metabolism among schizophrenia patients |
title_fullStr | Clinical and biochemical study of d-serine metabolism among schizophrenia patients |
title_full_unstemmed | Clinical and biochemical study of d-serine metabolism among schizophrenia patients |
title_short | Clinical and biochemical study of d-serine metabolism among schizophrenia patients |
title_sort | clinical and biochemical study of d-serine metabolism among schizophrenia patients |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391825/ https://www.ncbi.nlm.nih.gov/pubmed/28435276 http://dx.doi.org/10.2147/NDT.S126979 |
work_keys_str_mv | AT eltallawyhamdyn clinicalandbiochemicalstudyofdserinemetabolismamongschizophreniapatients AT saleemtahiah clinicalandbiochemicalstudyofdserinemetabolismamongschizophreniapatients AT elebidiabdallahmaa clinicalandbiochemicalstudyofdserinemetabolismamongschizophreniapatients AT hassanmohammedh clinicalandbiochemicalstudyofdserinemetabolismamongschizophreniapatients AT gabraromanyh clinicalandbiochemicalstudyofdserinemetabolismamongschizophreniapatients AT farghalywafaama clinicalandbiochemicalstudyofdserinemetabolismamongschizophreniapatients AT aboelmaalinagwa clinicalandbiochemicalstudyofdserinemetabolismamongschizophreniapatients AT sherkawyhodas clinicalandbiochemicalstudyofdserinemetabolismamongschizophreniapatients |